Traders Buy Large Volume of Put Options on Iqvia (NYSE:IQV)

Share on StockTwits

Iqvia Holdings Inc (NYSE:IQV) saw some unusual options trading on Monday. Investors bought 6,034 put options on the company. This is an increase of 5,240% compared to the typical volume of 113 put options.

A number of analysts have recently commented on the company. Credit Suisse Group upped their price target on Iqvia from $165.00 to $170.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. Wolfe Research raised Iqvia from a “peer perform” rating to an “outperform” rating in a research note on Thursday, November 14th. ValuEngine cut Iqvia from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. JPMorgan Chase & Co. increased their target price on Iqvia from $160.00 to $180.00 and gave the stock an “overweight” rating in a research note on Thursday, July 25th. Finally, Wells Fargo & Co increased their target price on Iqvia from $170.00 to $178.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. Three analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $166.46.

NYSE IQV opened at $142.81 on Tuesday. The business has a 50 day simple moving average of $145.02 and a 200 day simple moving average of $148.52. Iqvia has a 52-week low of $104.90 and a 52-week high of $164.13. The company has a debt-to-equity ratio of 1.85, a quick ratio of 1.12 and a current ratio of 1.12. The stock has a market cap of $28.43 billion, a price-to-earnings ratio of 27.89, a PEG ratio of 1.62 and a beta of 0.87.

Iqvia (NYSE:IQV) last posted its earnings results on Wednesday, October 30th. The medical research company reported $1.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.03. Iqvia had a return on equity of 16.95% and a net margin of 2.24%. The business had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.76 billion. During the same period in the prior year, the business earned $1.42 EPS. Iqvia’s revenue for the quarter was up 6.7% compared to the same quarter last year. On average, analysts predict that Iqvia will post 5.9 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in the business. CWM LLC boosted its position in Iqvia by 63.4% during the 2nd quarter. CWM LLC now owns 165 shares of the medical research company’s stock worth $27,000 after acquiring an additional 64 shares during the last quarter. Montag & Caldwell LLC boosted its position in Iqvia by 2.4% during the 2nd quarter. Montag & Caldwell LLC now owns 2,750 shares of the medical research company’s stock worth $442,000 after acquiring an additional 64 shares during the last quarter. Archford Capital Strategies LLC boosted its position in Iqvia by 1.8% during the 2nd quarter. Archford Capital Strategies LLC now owns 3,877 shares of the medical research company’s stock worth $624,000 after acquiring an additional 67 shares during the last quarter. Securian Asset Management Inc boosted its position in Iqvia by 0.4% during the 2nd quarter. Securian Asset Management Inc now owns 16,442 shares of the medical research company’s stock worth $2,646,000 after acquiring an additional 68 shares during the last quarter. Finally, Capital Investment Advisory Services LLC boosted its position in Iqvia by 46.0% during the 2nd quarter. Capital Investment Advisory Services LLC now owns 219 shares of the medical research company’s stock worth $34,000 after acquiring an additional 69 shares during the last quarter. 91.39% of the stock is owned by hedge funds and other institutional investors.

Iqvia Company Profile

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Recommended Story: Real Estate Investment Trust (REIT) ETF

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Brokerages Anticipate First Commonwealth Financial  to Announce $0.28 EPS
Brokerages Anticipate First Commonwealth Financial to Announce $0.28 EPS
Zacks: Navidea Biopharmaceuticals, Inc.  Given Consensus Rating of “Strong Buy” by Analysts
Zacks: Navidea Biopharmaceuticals, Inc. Given Consensus Rating of “Strong Buy” by Analysts
GCN Coin Reaches One Day Trading Volume of $29.00
GCN Coin Reaches One Day Trading Volume of $29.00
Bitcoin SV Price Down 5.6% This Week
Bitcoin SV Price Down 5.6% This Week
IGToken  Reaches One Day Trading Volume of $2,505.00
IGToken Reaches One Day Trading Volume of $2,505.00
OneConnect Financial Technology  Announces December 13th IPO
OneConnect Financial Technology Announces December 13th IPO


© 2006-2019 Ticker Report